PARENCHIMA WG3: Position paper Nicholas M Selby, Peter J Blankes7jn, Peter Boor, Chris7an Combe, Kai-Uwe Eckardt, Eli EikeAord, Nuria Garcia-Fernandez, Xavier Golay, Isky Gordon, Nicolas Grenier, Paul D Hockings, Jens Jenson, Jaap A Joles, Philip A Kalra, Bernhard K Krämer, Patrick B Mark, Iosif A Mendichovszky, Olivera Nikolic, Aghogho Odudu, Albert CM Ong, Alberto Or7z, Menno Pruijm, Giuseppe Remuzzi, Jarle Rørvik, Sophie de Seigneux, Roslyn J Simms, Janka Sla7nska, Paul Summers, Maarten W Taal, Harriet C Thoeny, Jean-Paul Vallée, Marcos Wolf, Anna Caroli, Steven Sourbron
Aims of position paper • Arose from Bergamo mee7ng • Enunciate the important clinical ques7ons that MRI could be used to answer, to direct future strategy in terms of study design and funding applica7ons • To agree principles around important aspects of study design • To publicise the group and our aims
Manuscript • Two sec7ons • Discussion of key clinical ques7ons • Renal MRI must cross two transla7onal gaps • Aiming to establish technical, biological and clinical valida7on, then move to clinical u7lity and health technology assessment • Subheadings: • Diagnos(c biomarkers: diagnosis and classifica(on of disease • Prognos(c biomarkers: predic(ng disease progression • Predic(ve biomarkers: pa(ent selec(on for treatment • Monitoring biomarkers: response to treatment • Safety biomarkers: detec(ng drug toxicity • Series of 14 recommenda7ons
Recommendations
Recommend
More recommend